ALX Oncology Announces Initiation Of Phase 2 Investigator-Sponsored Trial Of Neoadjuvant RadiationAand Evorpacept In Combination With Pembrolizumab In Patients With Untreated HPV-Mediated Oropharyngeal Cancer
ALX Oncology Announces Initiation Of Phase 2 Investigator-Sponsored Trial Of Neoadjuvant RadiationAand Evorpacept In Combination With Pembrolizumab In Patients With Untreated HPV-Mediated Oropharyngeal Cancer
ALX Oncology宣布启动由研究者赞助的新辅助放射和Evorpacept联合Pembrolizumab治疗未经治疗的HPV介导的口咽癌患者的2期试验
ALX Oncology Announces Initiation Of Phase 2 Investigator-Sponsored Trial Of Neoadjuvant RadiationAand Evorpacept In Combination With Pembrolizumab In Patients With Untreated HPV-Mediated Oropharyngeal Cancer
ALX Oncology宣布启动由研究者赞助的新辅助放射和Evorpacept联合Pembrolizumab治疗未经治疗的HPV介导的口咽癌患者的2期试验
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。